

Metabolic Code® MAX 12 PROBIOTIC

Strong Immune and Digestive Support*

- **Metabolic Code® Max 12 Probiotic** contains a diverse community of twelve beneficial bacteria that includes Kyo-Dophilus® Probiotic's proprietary strains known as The Friendly Trio® consisting of *L. gasseri* KS-13, *B. bifidum* G9-1, and *B. longum* MM-2. *B. infantis*, *B. breve*, and *L. rhamnosus* and other compatible species help populate the microbiome with beneficial bacteria to promote strong GI health and help maintain digestive and immune system balance.*
- **Metabolic Code® Max 12 Probiotic** 60 Billion CFU (Colony Forming Units) with Kyo-Dophilus® represents one of the strongest multi-strain probiotics available. High potency **Metabolic Code® Max 12 Probiotic** survives stomach acid,* encourages implantation and rapid replication in the gut for critical GI and immune support.* **Metabolic Code® Max 12 Probiotic** delivers efficacy,* quality, and extended live cell viability without refrigeration.
- Kyo-Dophilus' The Friendly Trio® is a clinically studied proprietary blend of human strain *Lactobacillus gasseri* KS-13, *Bifidobacterium bifidum* G9-1, and *Bifidobacterium longum* MM-2 proven to support digestive and immune function.*

SUGGESTED USE: Take one capsule with a meal daily. Not recommended for children under 12.

Supplement Facts

Serving Size: 1 delayed release capsule

Servings Per Container: 40

	Amount per serving	%DV
Proprietary Blend	60 billion live cells†	**
<i>Lactobacillus gasseri</i> KS-13, <i>Bifidobacterium bifidum</i> G9-1 and <i>Bifidobacterium longum</i> MM-2, UALp-05™ <i>Lactobacillus plantarum</i> , UALpc-04™ <i>Lactobacillus paracasei</i> , UABla-12™ <i>Bifidobacterium animalis</i> subsp. <i>Lactis</i> , <i>Bifidobacterium longum</i> BB536, UALa-01™ <i>Lactobacillus acidophilus</i> , <i>Bifidobacterium breve</i> M-16V, <i>Bifidobacterium infantis</i> M-63, <i>Lactobacillus gasseri</i> LAC-343, <i>Lactobacillus rhamnosus</i> LCS-742		
**Daily Value (DV) not established		

†Prior to expiration date

UALp-05, UALpc-04, UABla-12, and UALa-01 are trademarks of Chr. Hansen A/S.

Other ingredients: Starch (potato, tapioca, corn), Hypromellose (vegetable capsule), Silicon dioxide, Calcium phosphate.

Free of: GMOs, soy, gluten, dairy, sodium, preservatives, artificial colors, artificial flavors.

Warning: Consult your healthcare professional before using this or any product if you are pregnant, nursing, or under medical care.

Refrigeration not required. Store in a cool, dry place with cap tight.

Keep out of reach of children.

Safety Sealed: Do not use if cap drop ring or printed inner seal is broken or missing. Glass bottle, handle with care.

Manufactured by:


Wakunaga of America Co., Ltd.
Mission Viejo, CA 92691 USA
800.421.2998 www.kyolic.com

Distributed by:

Natural Formulations, LLC
Cincinnati, OH 45202 USA
www.metaboliccode.com

Product Code

633-94CX: 40 capsules



*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

INTENDED FOR PROFESSIONAL USE ONLY

Metabolic Code[®] MAX 12 PROBIOTIC

Strong Immune and Digestive Support*

Metabolic Code[®] Max 12 Probiotic containing a Proprietary Blend of *Lactobacillus gasseri* KS-13, *Bifidobacterium bifidum* G9-1 and *Bifidobacterium longum* MM-2, UALp-05™ *Lactobacillus plantarum*, UALpc-04™ *Lactobacillus paracasei*, UABla-12™ *Bifidobacterium animalis* subsp. *Lactis*, *Bifidobacterium longum* BB536, UALa-01™ *Lactobacillus acidophilus*, *Bifidobacterium breve* M-16V, *Bifidobacterium infantis* M-63, *Lactobacillus gasseri* LAC-343, *Lactobacillus rhamnosus* LCS-742 [60 billion live cells], is designed for strong immune and digestive support.*

***Lactobacillus gasseri* KS-13** and ***Bifidobacterium bifidum* G9-1** strains were shown to reduce both diarrhea and constipation in patients,¹⁻³ and alleviate symptoms of those with *Candida albicans*.⁴ The Friendly Trio, which also includes *L. gasseri* KS-13, *B. bifidum* G9-1 combined with ***Bifidobacterium longum* MM-2**, were clinically shown to prevent the occurrence of nosocomial infection in patients with hematologic and oncologic diseases,⁵ induce a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults,⁶ and improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies.⁷

***Bifidobacterium longum* BB536** appears to be effective in the treatment^{8,9} and exert positive influences on the formation of anti-allergic microbiota^{10,11} of Japanese cedar pollinosis in several clinical studies. *B. longum* BB536 may potentiate innate immunity by reducing the incidence of influenza and fever in elderly subjects,¹² may significantly decrease the cell numbers of enterotoxigenic bacteroides fragilis (ETBF) in the microbiota,¹³ increase the cell number of bifidobacteria in the intestinal microbiota,^{14,15} and modulate immune function¹⁴ and frequency of defecation¹⁵ in elderly patients receiving enteral tube feeding. Another benefit includes showing improved symptomatic gastrointestinal (GI) episodes after gastric bypass surgeries and initially improve quality of life (QoL).¹⁶

***Bifidobacterium breve* M-16V** administered to patients with atopic dermatitis with Bifidobacterium-deficient microflora was shown to significantly improve allergic symptoms¹⁷ and significantly increased fecal *B. breve* counts without adverse effects.¹⁸

A mixture of *B. longum* BB536, ***Bifidobacterium infantis* M-63** and *B. breve* M-16V were shown to decrease abdominal pain and improve QoL in those with irritable bowel syndrome¹⁹, and found safe and effective in the treatment of chronic constipation²⁰, and significantly improve allergic rhinitis (AR) symptoms and QoL in those with pollen-induced AR and intermittent asthma.²¹

***Bifidobacterium lactis* UABla-12™** was shown to improve abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.²²

Lactobacillus acidophilus*, *Lactobacillus paracasei*, *Lactobacillus plantarum species have been shown to positively modulate intestinal microflora, support a health inflammation response, improve symptoms of irritable bowel syndrome (IBS), enhance systematic immunity, and support regularity.²³⁻³⁶

References

1. In-House Clinical Study Conducted on 180 Patients from 8 Different Medical Facilities (Kobe University and associated hospitals).
2. Honma N, Ohtani K, et al. Part II. Clinical Effects. New Medicines and Clinics. 1987;36(1):75-80.
3. Willard T. Chiron Consultants Inc., Calgary, Canada. 1989.
4. Willard T. Chiron Consultants Inc., Calgary, Canada. 1989.
5. Simon AGL, Rogacion J. PIDSP J. 2005;9(2):12-18.
6. Spaiser SJ, Culpepper T, et al. J Am Coll Nutr. 2015;34(6):459-69.
7. Dennis-Wall JC, Culpepper T, et al. Am J Clin Nutr. 2017;105(3):758-67.
8. Xiao JZ, Kondo S, et al. Clin Exp Allergy. 2006;36(11):1425-35.
9. Xiao JZ, Kondo S, et al. Allergol Int. 2007;56(1):67-75.
10. Odamaki T, Xiao JZ, et al. J Investig Allergol Clin Immunol. 2007;17(2):92-100.
11. Odamaki T, Xiao JZ, et al. J Med Microbiol. 2007;56(Pt 10):1301-8.
12. Namba K, Hatano M, et al. Biosci Biotechnol Biochem. 2010;74(5):939-45.
13. Odamaki T, Sugahara H, et al. Anaerobe. 2012;18(1):14-8.
14. Akatsu H, Iwabuchi N, et al. JPEN J Parenter Enteral Nutr. 2013;37(5):631-40.
15. Kondo J, Xiao JZ, et al. World J Gastroenterol. 2013;19(14):2162-70.
16. Chen JC, Lee WJ, et al. Surg Obes Relat Dis. 2016;12(1):57-61.
17. Hattori K, Yamamoto A, et al. Areugi. 2003;52(1):20-30. [Article in Japanese].
18. Patole S, Keil AD, et al. PLoS One. 2014;9(3):e89511.
19. Giannetti E, Maglione M, et al. J Clin Gastroenterol. 2017;51(1):e5-e10
20. Russo M, Giugliano FP, et al. Ital J Pediatr. 2017;43(1):24. doi: 10.1186/s13052-017-0334-3.
21. Miraglia Del Guidice M, Indolfi C, et al. Ital J Pediatr. 2017;43(1):25. doi: 10.1186/s13052-017-0340-5.
22. Martoni CJ, Srivastava S, Leyer GJ. Nutrients. 2020;12(2):363. doi: 10.3390/nu12020363.
23. Harata G, Kumar H, et al. Eur J Nutr. 2017;56(7):2245-53.
24. Kawase M, He F, et al. Int J Food Microbiol. 2009;128(3):429-34.
25. Inoue Y, Kambara T, et al. Int Arch Allergy Immunol. 2014;165(4):247-54.
26. Ishida Y, Nakamura F, et al. J Dairy Sci. 2005;88(2):527-33.
27. Zhang H, Sun J, et al. J Microbiol. 2013;51(6):777-82.
28. Moroi M, Uchi S, et al. J Dermatol. 2011;38(2):131-9.
29. Peng GC, Hsu CH. Pediatr Allergy Immunol. 2005;16(5):433-8.
30. Ducrotté P, Sawant P, et al. World J Gastroenterol. 2012;18(30):4012-8.
31. Bosch M, Méndez M, et al. Nutr Hosp. 2012;27(2):504-9.
32. Mañé J, Pedrosa E, et al. Nutr Hosp. 2011;26(1):228-35.
33. Eskesen D, Jespersen L, et al. Br J Nutr. 2015;114(10):1638-46.
34. Singh A, Haciní-Rachinel F, et al. Eur J Clin Nutr. 2013;67(2):161-7.
35. Lee A, Lee YJ, et al. Nutrients. 2017;9(6). Pii: E558. doi: 10.3390/nu9060558.
36. Williams EA, Stimpson J, et al. Ailment Pharmacol Ther. 2009;29(1):97-103.

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.

INTENDED FOR PROFESSIONAL USE ONLY